microbiota for Clinical Studies - Medical / Health Care - Clinical Services
Our platform delivers investigational medicinal products that contain diverse and viable communities of donor-derived microorganisms that target multiple functional pathways. We believe that this approach is superior to others being pursued and provides the company with numerous competitive advantages, including: de-risking of clinical programmes based on IMT precedence, accelerated clinical development and opportunities to discover second and third generation products through data generated from clinical studies.
In contrast to traditional pharmaceuticals - which target a singular pathway, the inherent complexity of our products mean they can target multiple disease pathways, thus having broad therapeutic utility and powerful effects in specific patient populations.
The platform and supply chain underpinning the production of our lead asset, EBX-101, is at the heart of EnteroBiotix. We believe that our know-how, IP and capabilities will position EnteroBiotix as not only a pioneer in the field but also a global leader.
We have created a trademark protected donor brand and online portal for recruiting healthy donors to donate starting material called Number 2. We have developed processes and procedures that integrate with this portal to ensure that the recruitment processed is efficient and that yields are maximised from active donors.
Our MHRA-licensed cleanroom facility in Aberdeen ensures that starting material is checked in, tested and processed in a compliant manner to high standards. Our capabilities in Glasgow will allow us to manufacture drug substance and drug product to meet the needs of our internal and partnered programmes.